Clover Health published a supplemental Q&A document to address frequently asked shareholder questions following its third quarter 2026 earnings announcement. The update discusses long-term projections through 2028, membership cohort maturation, and plans to improve the company's Adjusted SG&A ratio through operating leverage as it scales.
Clover Health Investments, Corp. is a remote-first healthcare technology company that operates as a large accelerated filer. As of October 30, 2026, the company had 439,707,261 shares of Class A and 95,713,497 shares of Class B common stock outstanding. The filing highlights the expansion of its Clover Assistant technology under the brand name Counterpart Assistant for external payors and providers.
Clover Health reported Q3 2026 financial results, achieving GAAP net income of $6 million and total revenue growth of 53% year-over-year to $759.3 million. The company raised its full-year 2026 guidance, now expecting total revenues between $2.97 billion and $3.00 billion and its first full year of GAAP net income profitability. Alongside the results, the company appointed Interim CFO Joseph Clay Thornton to the role on a permanent basis.
Term
Q3 2026
“Our results further demonstrate our technology-powered differentiation, and how earlier and better care management, market-leading growth, and increasing profitability can reinforce one another under the right model.”
Andrew Toy, Clover Health CEO
“In 2026, Clover is on track to have grown significantly and expects to deliver its first full year of GAAP Net Income profitability. With our largest member cohorts maturing, continued operating leverage, and strong Star ratings performance, we believe we are well positioned for meaningful earnings expansion in 2027.”
Clover Health Investments CLO Karen Soares Sells $89.8K of Stock
Karen Soares, CLO, sold 19,275 shares of Clover Health Investments, Corp. at $4.66 a share, worth $89.8K in total on Oct 20, 2026. Shares held after the trade: 1,573,423 (-1.2%).
Clover Health Investments CEO, Medicare Advantage Jamie L. Reynoso Sells $17.9K of Stock
Jamie L. Reynoso, CEO, Medicare Advantage, sold 4,066 shares of Clover Health Investments, Corp. at $4.41 a share, worth $17.9K in total on Oct 19, 2026. Shares held after the trade: 2,770,351 (-0.1%).
Clover Health Investments CEO Andrew Toy Sells $291K of Stock
Andrew Toy, CEO, sold 62,176 shares of Clover Health Investments, Corp. at $4.68 a share, worth $291K in total on Oct 15, 2026. Shares held after the trade: 9,078,334 (-0.7%).
Clover Health Investments CLO Karen Soares Sells $68.7K of Stock
Karen Soares, CLO, sold 14,673 shares of Clover Health Investments, Corp. at $4.68 a share, worth $68.7K in total on Oct 15, 2026. Shares held after the trade: 1,592,698 (-0.9%).
Clover Health Investments Interim CFO Joseph Clay Thornton Sells $21.5K of Stock
Joseph Clay Thornton, Interim CFO, sold 4,591 shares of Clover Health Investments, Corp. at $4.68 a share, worth $21.5K in total on Oct 15, 2026. Shares held after the trade: 1,244,935 (-0.4%).
Clover Health Investments CEO, Counterpart Health Conrad Wai Sells $111K of Stock
Conrad Wai, CEO, Counterpart Health, sold 23,627 shares of Clover Health Investments, Corp. at $4.68 a share, worth $111K in total on Oct 15, 2026. Shares held after the trade: 1,042,072 (-2.2%).
Clover Health Investments CEO, Medicare Advantage Jamie L. Reynoso Sells $85.5K of Stock
Jamie L. Reynoso, CEO, Medicare Advantage, sold 18,273 shares of Clover Health Investments, Corp. at $4.68 a share, worth $85.5K in total on Oct 15, 2026. Shares held after the trade: 2,774,417 (-0.7%).
Clover Health announced that CMS awarded its PPO Medicare Advantage plans a 5-star rating and its HMO plan a 4.5-star rating for 2027. The 5-star rating for the PPO plans, which cover ~98% of the company's members, allows for year-round enrollment and higher quality-based payments in 2028. The rating calculation was impacted by a court decision removing 20 specific measures currently under appeal.
Clover Health Investments CEO, Medicare Advantage Jamie L. Reynoso Sells $38.7K of Stock
Jamie L. Reynoso, CEO, Medicare Advantage, sold 8,750 shares of Clover Health Investments, Corp. at $4.42 a share, worth $38.7K in total on Oct 5, 2026. Shares held after the trade: 2,794,696 (-0.3%).
Clover Health Investments CEO Andrew Toy Sells $1.34M of Stock
Andrew Toy, CEO, sold 318,806 shares of Clover Health Investments, Corp. at $4.19 a share, worth $1.34M in total on Oct 1, 2026. Shares held after the trade: 9,140,510 (-3.4%).
Clover Health has appointed former U.S. Senator Robert Torricelli and Dr. Brian J. Miller to its Board of Directors, filling two previously disclosed vacancies. Senator Torricelli will serve on the Audit Committee, while Dr. Miller joins the Clinical Committee, bringing the total board count to nine directors. The appointments aim to strengthen the company's expertise in federal policy, clinical medicine, and Medicare Advantage regulation.
Clover Health appointed former U.S. Senator Robert Torricelli and Dr. Brian J. Miller to its Board of Directors, filling two vacancies and bringing the board to nine members. Senator Torricelli will serve on the Audit Committee, while Dr. Miller joins the Clinical Committee, bringing expertise in federal policy, clinical medicine, and healthcare regulation. Both directors will receive pro-rated annual retainers and restricted stock units valued at $200,000 for their service through 2026.
Clover Health Investments CEO, Counterpart Health Conrad Wai Sells $1.42M of Stock
Conrad Wai, CEO, Counterpart Health, sold 300,000 shares of Clover Health Investments, Corp. at $4.72 a share, worth $1.42M in total on Sep 15, 2026. Shares held after the trade: 1,170,056 (-20.4%).